Reducing levels of amyloid-B, the peptide that accumulates and causes Alzheimer's disease, is the most likely method to treat or prevent this disease. Our preliminary data demonstrates that postsynaptic signaling mechanisms, mainly through NMDA and orexin receptors, can dramatically reduce AB production and levels. We propose that both of these neurotransmitter systems activate substantially different signaling cascades that eventually converge on the extracellular-regulated kinase (ERK) signaling pathway. Activation of the ERK signaling cascade rapidly and dramatically reduces AB levels in vivo. This proposal will determine the cellular pathways that link these neurotransmitter receptors to ERK and AB metabolism. Understanding these pathways will provide insight into factors that contribute to disease risk as well as provide new pathways that could be targeted for therapeutic inten/enfion to treat AD.

Public Health Relevance

Reducing levels of amyloid-B (AB), the peptide that accumulates and causes Alzheimer's disease, is the most likely method to treat or prevent this disease. Our preliminary data demonstrates that certain neurotransmitter receptors can reduce AP levels in living mice. This proposal will determine the cellular pathways that link these receptors to Ap metabolism. This could lead to new avenues for therapeutic intervention

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Research Program Projects (P01)
Project #
5P01NS074969-03
Application #
8642681
Study Section
National Institute of Neurological Disorders and Stroke Initial Review Group (NSD)
Project Start
Project End
Budget Start
2014-05-01
Budget End
2015-04-30
Support Year
3
Fiscal Year
2014
Total Cost
$207,467
Indirect Cost
$50,625
Name
Washington University
Department
Type
DUNS #
068552207
City
Saint Louis
State
MO
Country
United States
Zip Code
63130
Zhao, Na; Liu, Chia-Chen; Qiao, Wenhui et al. (2018) Apolipoprotein E, Receptors, and Modulation of Alzheimer's Disease. Biol Psychiatry 83:347-357
Musiek, Erik S; Bhimasani, Meghana; Zangrilli, Margaret A et al. (2018) Circadian Rest-Activity Pattern Changes in Aging and Preclinical Alzheimer Disease. JAMA Neurol 75:582-590
Kress, Geraldine J; Liao, Fan; Dimitry, Julie et al. (2018) Regulation of amyloid-? dynamics and pathology by the circadian clock. J Exp Med 215:1059-1068
Ogaki, Kotaro; Martens, Yuka A; Heckman, Michael G et al. (2018) Multiple system atrophy and apolipoprotein E. Mov Disord 33:647-650
Liao, Fan; Li, Aimin; Xiong, Monica et al. (2018) Targeting of nonlipidated, aggregated apoE with antibodies inhibits amyloid accumulation. J Clin Invest 128:2144-2155
Kang, S S; Ren, Y; Liu, C-C et al. (2018) Lipocalin-2 protects the brain during inflammatory conditions. Mol Psychiatry 23:344-350
Hettinger, Jane C; Lee, Hyo; Bu, Guojun et al. (2018) AMPA-ergic regulation of amyloid-? levels in an Alzheimer's disease mouse model. Mol Neurodegener 13:22
Yuede, Carla M; Timson, Benjamin F; Hettinger, Jane C et al. (2018) Interactions between stress and physical activity on Alzheimer's disease pathology. Neurobiol Stress 8:158-171
Roe, Catherine M; Barco, Peggy P; Head, Denise M et al. (2017) Amyloid Imaging, Cerebrospinal Fluid Biomarkers Predict Driving Performance Among Cognitively Normal Individuals. Alzheimer Dis Assoc Disord 31:69-72
Czirr, Eva; Castello, Nicholas A; Mosher, Kira I et al. (2017) Microglial complement receptor 3 regulates brain A? levels through secreted proteolytic activity. J Exp Med 214:1081-1092

Showing the most recent 10 out of 85 publications